A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors
A multicenter, open-label, phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YH002 in combination with YH001 in subjects with advanced solid tumors
Advanced Solid Tumor
DRUG: A:YH002+YH001|DRUG: B:YH002+YH001|DRUG: YH002+YH001
Determined the maximum tolerated dose (MTD), The safety profile of combination treatment will be assessed by monitoring the adverse events (AE) per NCI CTCAE v5.0, Up to 1 year after the last dosing|Determined the recommended Phase II dose (RP2D), The safety profile of combination treatment will be assessed by monitoring the adverse events (AE) per NCI CTCAE v5.0, Up to 1 year after the last dosing
A multicenter, open-label, phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YH002 in combination with YH001 in subjects with advanced solid tumors